MA33534B1 - Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine - Google Patents

Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine

Info

Publication number
MA33534B1
MA33534B1 MA34641A MA34641A MA33534B1 MA 33534 B1 MA33534 B1 MA 33534B1 MA 34641 A MA34641 A MA 34641A MA 34641 A MA34641 A MA 34641A MA 33534 B1 MA33534 B1 MA 33534B1
Authority
MA
Morocco
Prior art keywords
human
antibodies
angiobots
high affinity
affinity against
Prior art date
Application number
MA34641A
Other languages
Arabic (ar)
English (en)
Inventor
Gavin Thurston
Christopher Daly
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33534(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA33534B1 publication Critical patent/MA33534B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES ANTICORPS QUI SE LIENT À L'ANGIOPOÏÉTINE 2 (ANG-2) ET DES MÉTHODES POUR LES UTILISER. SELON CERTAINS MODES DE RÉALISATION DE L'INVENTION, LES ANTICORPS SONT DES ANTICORPS TOTALEMENT HUMAINS QUI SE LIENT À L'ANG-2 HUMAINE. LES ANTICORPS DE L'INVENTION SONT UTILES, ENTRE AUTRES, POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À UNE OU PLUSIEURS DES ACTIVITÉS BIOLOGIQUES DE L'ANG-2 Y COMPRIS L'ANGIOGENÈSE.
MA34641A 2009-07-29 2012-02-16 Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine MA33534B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22941809P 2009-07-29 2009-07-29
US29519410P 2010-01-15 2010-01-15
PCT/US2010/043295 WO2011014469A1 (fr) 2009-07-29 2010-07-27 Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine

Publications (1)

Publication Number Publication Date
MA33534B1 true MA33534B1 (fr) 2012-08-01

Family

ID=42937802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34641A MA33534B1 (fr) 2009-07-29 2012-02-16 Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine

Country Status (40)

Country Link
US (4) US8987420B2 (fr)
EP (1) EP2459592B1 (fr)
JP (1) JP5701876B2 (fr)
KR (1) KR101781786B1 (fr)
CN (2) CN102549015B (fr)
AR (1) AR077333A1 (fr)
AU (1) AU2010276544B2 (fr)
BR (1) BR112012001984B8 (fr)
CA (1) CA2769334C (fr)
CL (1) CL2012000229A1 (fr)
CO (1) CO6491118A2 (fr)
CR (1) CR20120086A (fr)
CY (1) CY1117695T1 (fr)
DK (1) DK2459592T3 (fr)
EC (1) ECSP12011694A (fr)
ES (1) ES2582405T3 (fr)
HR (1) HRP20161043T1 (fr)
HU (1) HUE030508T2 (fr)
IL (1) IL217680A (fr)
JO (1) JO3182B1 (fr)
MA (1) MA33534B1 (fr)
ME (1) ME02484B (fr)
MX (1) MX2012001094A (fr)
MY (1) MY156816A (fr)
NI (1) NI201200014A (fr)
NZ (1) NZ598202A (fr)
PE (1) PE20121129A1 (fr)
PH (1) PH12012500171A1 (fr)
PL (1) PL2459592T3 (fr)
PT (1) PT2459592T (fr)
RS (1) RS55054B1 (fr)
RU (1) RU2545399C2 (fr)
SG (1) SG178114A1 (fr)
SI (1) SI2459592T1 (fr)
SM (1) SMT201600251B (fr)
TN (1) TN2012000040A1 (fr)
TW (1) TWI527591B (fr)
UY (1) UY32812A (fr)
WO (1) WO2011014469A1 (fr)
ZA (1) ZA201200658B (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004106375A1 (fr) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9512220B2 (en) 2011-04-05 2016-12-06 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP3415533A1 (fr) 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anticorps anti-tie2 et utilisations associées
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PL2831111T3 (pl) 2012-03-30 2019-09-30 Boehringer Ingelheim International Gmbh Cząsteczki wiążące Ang2
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
EP2891497B1 (fr) * 2012-08-31 2020-07-01 Osaka University Vaccin à base d'adn contenant un épitope spécifique du vegf et/ou un épitope spécifique de l'angiopoïétine-2
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014049100A1 (fr) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Combinaisons pharmaceutiques comprenant des liants doubles angiopoïétine-2/dll4 et des agents anti-vegf
US20140093498A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
MX2015005546A (es) 2012-11-13 2015-08-05 Regeneron Pharma Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
WO2014144791A2 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EA201592157A1 (ru) 2013-06-07 2016-05-31 Дзе Калифорния Инститъют Фор Биомедикал Рисёрч Низкомолекулярные ингибиторы фиброза
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) * 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
WO2015049517A2 (fr) 2013-10-01 2015-04-09 Kymab Limited Modèles d'animaux et molécules thérapeutiques
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CA2928852A1 (fr) * 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Interventions a base d'angiopoietine pour le traitement de la malaria cerebrale
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
EP3116903A2 (fr) 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Compositions vaccinales et méthodes pour rétablir la fonction de la voie nkg2d contre les cancers
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3139956A4 (fr) * 2014-05-07 2017-11-29 Medimmune, LLC Méthodes d'utilisation d'anticorps anti-ang2
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
EP3207059A1 (fr) 2014-10-17 2017-08-23 Amgen Inc. Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 pour thérapies oculaires
WO2016073157A1 (fr) * 2014-11-06 2016-05-12 Genentech, Inc. Anticorps anti-ang2 et procédés d'utilisation de ces anticorps
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3250036B1 (fr) 2014-12-10 2021-05-12 The Scripps Research Institute Inhibiteurs de fibrose à petites molécules
WO2016115218A1 (fr) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Conjugués anticorps-médicament pour le traitement d'états immunitaires
US20160208018A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CA2978340C (fr) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Derives de maytansinoide, conjugues de ceux-ci, et procedes d'utilisation
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
HK1255056A1 (zh) 2015-09-16 2019-08-02 Ablexis, Llc 抗cd115抗体
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
MY200764A (en) 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
JP7029401B2 (ja) 2016-02-02 2022-03-03 フレッド ハッチンソン キャンサー リサーチ センター 抗ｒｏｒ１抗体およびその使用
CA3027121A1 (fr) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anticorps anti-gitr et leurs utilisations
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
KR102520731B1 (ko) 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
EP3538557A4 (fr) * 2016-11-08 2020-11-18 Ablexis, LLC Anticorps anti-cd47
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
MX389729B (es) 2017-05-06 2025-03-20 Regeneron Pharma Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares.
WO2019006162A1 (fr) 2017-06-28 2019-01-03 Bluefin Biomedicine, Inc. Anticorps anti-ly6h et conjugués anticorps-médicament
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
CN110662771B (zh) * 2018-02-01 2023-07-28 南京驯鹿生物技术股份有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
KR102497171B1 (ko) * 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
EP3774866A1 (fr) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Récepteurs d'antigènes chimériques inactivables hétérodimères
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
WO2019235856A1 (fr) 2018-06-07 2019-12-12 기초과학연구원 Anticorps se liant à tie2 et son utilisation
EP3805265A4 (fr) 2018-06-07 2022-07-06 Institute for Basic Science Anticorps se liant à tie2 et son utilisation
EA202192103A1 (ru) 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
KR20210130755A (ko) 2019-02-21 2021-11-01 리제너론 파마슈티칼스 인코포레이티드 항-met 항체 및 met에 결합하는 이중특이적 항원 결합 분자를 사용하여 안구암을 치료하는 방법
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
WO2020232243A2 (fr) * 2019-05-14 2020-11-19 Froude Jeffrey W Anticorps contre le virus ebola et soudan
JP7680967B2 (ja) * 2019-06-14 2025-05-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｐｄ－１に対する抗体およびその使用方法
EP3986933A1 (fr) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
JP7743314B2 (ja) 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021123908A1 (fr) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Thérapie à base de lymphocytes car-t ciblant l'antigène ngcgm3
CA3166619A1 (fr) 2020-02-28 2021-09-02 Julian Andreev Molecules bispecifiques de liaison a l'antigene qui se lient a her2, et leurs procedes d'utilisation
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.
JP7809068B2 (ja) * 2020-04-24 2026-01-30 メモリアル スローン ケタリング キャンサー センター Ｃｄ１９を標的とするキメラ抗原受容体およびその使用
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
US12605459B2 (en) 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
JP7765457B2 (ja) * 2020-08-06 2025-11-06 ステレクシス セラピューティクス，エルエルシー Ｉｌ－８抗体及びその使用方法
CN116472285A (zh) * 2020-08-07 2023-07-21 南京金斯瑞生物科技有限公司 针对人血管生成素-2的抗体及其用途
UY39415A (es) 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
WO2022056197A1 (fr) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Molécules de ciblage immunitaire et leurs utilisations
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.
JP7894873B2 (ja) 2021-01-25 2026-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
EP4330411B1 (fr) 2021-04-27 2026-03-18 4D Molecular Therapeutics Inc. Compositions et méthodes pour le traitement d'une maladie oculaire associée à l'angiogenèse
JP2024527235A (ja) 2021-06-22 2024-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ＥＧＦＲｖＩＩＩ抗体薬物コンジュゲート及びその使用
JP2024534159A (ja) * 2021-08-23 2024-09-18 アビラマックス・バイオファーマ・インコーポレイテッド 導入遺伝子発現のための組成物および方法
WO2023025194A1 (fr) * 2021-08-24 2023-03-02 江苏恒瑞医药股份有限公司 Molécule de liaison à fap/cd40 et son utilisation médicinale
CN120329435A (zh) * 2021-11-26 2025-07-18 三优生物医药(上海)有限公司 抗ang2抗体及其用途
MX2024008640A (es) 2022-01-12 2024-07-24 Regeneron Pharma Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso.
WO2023196903A1 (fr) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Molécules bispécifiques de liaison à l'antigène qui se lient et cd3 et antigènes associés à une tumeur (taa) et leurs utilisations
AU2023264772A1 (en) 2022-05-02 2024-10-24 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
WO2023240109A1 (fr) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Molécules multispécifiques pour moduler l'activité des lymphocytes t, et leurs utilisations
EP4626553A2 (fr) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Agonistes de tlr7 et conjugués anticorps-médicament associés
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用
WO2024138000A1 (fr) 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Promédicaments d'inhibiteur de topoisomérase i pour des conjugués adc et leurs procédés d'utilisation
EP4725969A1 (fr) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Conjugué anticorps-médicament bispécifique complémentaire anti-her2, son procédé de préparation et son utilisation
CN116789813B (zh) * 2023-06-27 2024-04-26 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用
WO2025117727A1 (fr) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogues d'agents cytotoxiques quinoxaline/quinoléine, conjugués lieur-agents, conjugués protéine-médicament et leurs utilisations
WO2025186364A1 (fr) 2024-03-06 2025-09-12 Jeansson Marie Anticorps ciblant angpt2 destinés à être utilisés dans le traitement de maladies fibrotiques, en particulier d'une ou de plusieurs maladies rénales, d'un ou plusieurs troubles ou d'une lésion associés à une fibrose rénale
WO2026078631A2 (fr) 2024-10-10 2026-04-16 University Of Lausanne Récepteurs antigéniques chimériques activables

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2519875C (fr) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Methode favorisant la regression de tumeurs au moyen d'inhibiteurs du vegf (facteur de croissance de l'endothelium vasculaire)
EP1740946B1 (fr) 2004-04-20 2013-11-06 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
EP1962903B1 (fr) 2005-12-15 2013-03-13 MedImmune Limited Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
SG176219A1 (en) * 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
SI2459592T1 (sl) 2016-07-29
CA2769334A1 (fr) 2011-02-03
PE20121129A1 (es) 2012-09-04
CL2012000229A1 (es) 2012-10-05
DK2459592T3 (en) 2016-08-29
NZ598202A (en) 2013-12-20
KR20120087891A (ko) 2012-08-07
ZA201200658B (en) 2012-10-31
US20110027286A1 (en) 2011-02-03
CR20120086A (es) 2012-06-01
CN102549015B (zh) 2014-10-15
CN104258390B (zh) 2017-09-08
JO3182B1 (ar) 2018-03-08
US9938339B2 (en) 2018-04-10
AR077333A1 (es) 2011-08-17
US20180186869A1 (en) 2018-07-05
RU2545399C2 (ru) 2015-03-27
ES2582405T3 (es) 2016-09-12
KR101781786B1 (ko) 2017-09-26
CO6491118A2 (es) 2012-07-31
ME02484B (fr) 2017-02-20
BR112012001984B1 (pt) 2020-10-27
ECSP12011694A (es) 2012-04-30
US8987420B2 (en) 2015-03-24
CN104258390A (zh) 2015-01-07
MY156816A (en) 2016-03-31
NI201200014A (es) 2012-05-29
BR112012001984B8 (pt) 2021-05-25
CA2769334C (fr) 2018-06-12
JP5701876B2 (ja) 2015-04-15
WO2011014469A1 (fr) 2011-02-03
HK1205470A1 (en) 2015-12-18
AU2010276544A1 (en) 2012-03-01
PT2459592T (pt) 2016-08-17
US20150152177A1 (en) 2015-06-04
EP2459592B1 (fr) 2016-05-18
TN2012000040A1 (en) 2013-09-19
RU2012107286A (ru) 2013-09-10
TW201116296A (en) 2011-05-16
US10875911B2 (en) 2020-12-29
IL217680A (en) 2016-04-21
AU2010276544B2 (en) 2014-03-27
US20210101969A1 (en) 2021-04-08
JP2013500970A (ja) 2013-01-10
SMT201600251B (it) 2016-08-31
TWI527591B (zh) 2016-04-01
SG178114A1 (en) 2012-03-29
PL2459592T3 (pl) 2016-11-30
MX2012001094A (es) 2012-03-14
PH12012500171A1 (en) 2016-03-04
CY1117695T1 (el) 2017-05-17
HUE030508T2 (en) 2017-05-29
UY32812A (es) 2011-04-29
RS55054B1 (sr) 2016-12-30
EP2459592A1 (fr) 2012-06-06
CN102549015A (zh) 2012-07-04
HK1166806A1 (zh) 2012-11-09
HRP20161043T1 (hr) 2016-10-21

Similar Documents

Publication Publication Date Title
MA37945A1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
MY165273A (en) Anti-cd48 antibodies and uses thereof
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
MA31838B1 (fr) Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA31767B1 (fr) Composes organiques et leurs utilisations
MA32654B1 (fr) Composés modulant sélectivement le récepteur cb2
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
TN2010000068A1 (en) Anticorps anti-cd37
MA32802B1 (fr) Anticorps humains à affinité élevée pour le récepteur de il-4 humain
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MA38478A1 (fr) Anticorps anti-pac1 humains
MA47221A1 (fr) Anticorps monoclonal à pd-l1
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38161A1 (fr) Anticorps anti-bmp-6
TW200603828A (en) Treatment of disorders
MA69688B1 (fr) Anticorps monoclonaux anti-gprc5d et leurs utilisations